Autopsy report · NCT05358249

Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

“Business reasons and not based on any safety concerns.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 6 months before it started.
• Ran for about 3 years 11 months before it stopped.
• 74 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Novartis Pharmaceuticals

Sponsor type

Industry

Conditions

KRAS G12C Mutant Solid Tumors; Carcinoma, Non-Small Cell Lung; Carcinoma, Non-Small-Cell Lung; Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma; Nonsmall Cell Lung Cancer

Interventions

JDQ443; trametinib; Ribociclib; cetuximab

Participants

74

Sites

13

Countries

Belgium, France, Germany, Italy, Singapore, South Korea, Spain, United States

Trials that died the same way

• Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors
  “Business reasons and not due to any safety concerns” (94% match in meaning)
• A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
  “business decision, not safety reasons.” (86% match in meaning)
• Phase 1/2 Study of USL311 +/- Lomustine in Advanced Solid Tumors or Relapsed/Recurrent Glioblastoma Multiforme (GBM)
  “Business reasons not related to safety” (84% match in meaning)
• Study of Poziotinib in Japanese Patients With NSCLC
  “Business decision, not related to safety.” (75% match in meaning)
• Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation
  “Company decision not related to any safety concerns.” (74% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.